CONBRIZA
País: Israel
Idioma: anglès
Font: Ministry of Health
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
BAZEDOXIFENE AS ACETATE 20 MG
Disponible des:
NEOPHARM LTD
Codi ATC:
G03XC02
formulario farmacéutico:
COATED TABLETS
Vía de administración:
PER OS
Fabricat per:
PFIZER IRELAND PHARMACEUTICALS
Grupo terapéutico:
BAZEDOXIFENE
indicaciones terapéuticas:
CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit
Data d'autorització:
2013-04-01
